By creator to www.biospace.com
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a number one precision medication firm targeted on the invention, growth, and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers, right now introduced the enrollment of the primary affected person within the Molecular Evaluation and Profiling of Liver Transplant Recipients (MAPLE) Examine at Mount Sinai Hospital in New York.
MAPLE is a multi-center, potential examine of the LiverCare platform, a novel multi-modality method to evaluate the standing of liver allografts. LiverCare will embody the next:
- AlloSure® Liver — donor-derived cell-free DNA-based measure of organ harm
- AlloMap® Liver — gene expression profiling evaluation of recipient immune system exercise
- AlloHeme™ Liver — blood-based micro-chimerism surveillance resolution
- HistoMap Liver — tissue-based gene expression profiling evaluation of allograft rejection and harm
- AlloID™ — blood-based metagenomic infectious illness identification
As well as, LiverCare features a proprietary machine studying algorithm to foretell allograft outcomes primarily based on scientific parameters.
The examine, which was first introduced earlier this yr, will enroll 1500 liver transplant recipients and marks the start of CareDx’s work in liver transplant. The primary enrolled affected person demonstrates the continued momentum behind the examine and CareDx’s dedication to affected person care throughout transplant organ varieties.
“MAPLE will assist us outline the appliance of multi-modality testing in liver transplant,” mentioned Dr. Sham Dholakia, Senior Vice President of Medical Affairs at CareDx. “As leaders in transplantation, CareDx was first to market with surveillance assessments supported by scientific information in kidney and coronary heart, and we’re main in lung. We are going to proceed to put money into scientific information growth and comply with the science in assist of transplant sufferers.”
“We’re excited to work with CareDx on the MAPLE Examine,” mentioned Dr. Sander Florman, MAPLE’s Principal Investigator and the Director of the Recanati/Miller Transplantation Institute. “Having seen the scientific information supporting use of CareDx’s assessments in coronary heart, kidney, and lung transplant, we’re extremely to review the potential advantages for the administration of liver transplant sufferers.”
CareDx, Inc., headquartered in South San Francisco, California, is a number one precision medication options firm targeted on the invention, growth and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers. CareDx presents testing companies, merchandise, and digital healthcare options alongside the pre- and post-transplant affected person journey and is the main supplier of genomics-based info for transplant sufferers. For extra info, please go to: www.CareDx.com.
Ahead Trying Statements
This press launch contains forward-looking statements, together with statements concerning the Firm’s continued enrollment within the LiverCare examine and the potential advantages of MAPLE. These forward-looking statements are primarily based upon info that’s presently out there to CareDx and its present expectations, communicate solely as of the date hereof, and are topic to quite a few dangers and uncertainties, together with dangers that the CareDx doesn’t understand the anticipated advantages of the enrollment; basic financial and market components; and different dangers mentioned in CareDx’s filings with the SEC, together with the Annual Report on Kind 10-Ok for the fiscal yr ended December 31, 2020 filed by CareDx with the SEC on February 24, 2021 and different reviews that CareDx has filed with the SEC. Any of those might trigger CareDx’s precise outcomes, efficiency or achievements to vary materially and adversely from these anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, besides as required by legislation, or endeavor to replace or revise any such forward-looking statements.
Chief Advertising Officer
— to www.biospace.com